TTM
$12.61B
YoY change
+0.1%
5Y CAGR
+11.4%
Peak year (2021)
$13.35B
Cumulative gross profit
$101.95B
Gross Profit history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: $12.24B
Gross Profit growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: +0.1%
Gross Profit history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | $12.24B | +0.1% | +$10.70M | ||
| 2024 | $12.23B | +12.5% | +$1.36B | ||
| 2023 | $10.87B | +3.9% | +$405.00M | ||
| 2022 | $10.47B | -21.6% | −$2.88B | ||
| 2021 | $13.35B | +86.9% | +$6.21B | ||
| 2020 | $7.14B | +27.9% | +$1.56B | ||
| 2019 | $5.58B | -8.9% | −$546.30M | ||
| 2018 | $6.13B | +15.0% | +$798.80M | ||
| 2017 | $5.33B | +19.6% | +$873.71M | ||
| 2016 | $4.46B | +22.5% | +$819.88M | ||
| 2015 | $3.64B | +41.9% | +$1.07B | ||
| 2014 | $2.56B | +34.3% | +$653.67M | ||
| 2013 | $1.91B | +51.8% | +$651.10M | ||
| 2012 | $1.26B | +206.2% | +$846.56M | ||
| 2011 | $410.53M | -6.1% | −$26.77M | ||
| 2010 | $437.29M | +20.4% | +$73.96M | ||
| 2009 | $363.33M | +60.6% | +$137.09M | ||
| 2008 | $226.25M | — | +$226.25M | ||
| 2007 | $0.00 | -100.0% | −$40.71M | ||
| 2006 | $40.71M | -1.0% | −$423.00K | ||
| 2005 | $41.13M | +81.1% | +$18.42M | ||
| 2004 | $22.71M | -55.3% | −$28.11M | ||
| 2003 | $50.82M | +227.8% | +$35.32M | ||
| 2002 | $15.51M | +0.3% | +$41.00K | ||
| 2001 | $15.46M | -64.6% | −$28.25M | ||
| 2000 | $43.71M | +41.5% | +$12.81M | ||
| 1999 | $30.90M | -6.9% | −$2.30M | ||
| 1998 | $33.20M | +8.9% | +$2.70M | ||
| 1997 | $30.50M | +32.6% | +$7.50M | ||
| 1996 | $23.00M | -16.1% | −$4.40M | ||
| 1995 | $27.40M | +18.1% | +$4.20M | ||
| 1994 | $23.20M | +118.9% | +$12.60M | ||
| 1993 | $10.60M | -7.8% | −$900.00K | ||
| 1992 | $11.50M | -309.1% | +$17.00M | ||
| 1991 | −$5.50M | +323.1% | −$4.20M | ||
| 1990 | −$1.30M | — | — |
- 2025$12.24B+0.1%
- 2024$12.23B+12.5%
- 2023$10.87B+3.9%
- 2022$10.47B-21.6%
- 2021$13.35B+86.9%
- 2020$7.14B+27.9%
- 2019$5.58B-8.9%
- 2018$6.13B+15.0%
- 2017$5.33B+19.6%
- 2016$4.46B+22.5%
- 2015$3.64B+41.9%
- 2014$2.56B+34.3%
- 2013$1.91B+51.8%
- 2012$1.26B+206.2%
- 2011$410.53M-6.1%
- 2010$437.29M+20.4%
- 2009$363.33M+60.6%
- 2008$226.25M—
- 2007$0.00-100.0%
- 2006$40.71M-1.0%
- 2005$41.13M+81.1%
- 2004$22.71M-55.3%
- 2003$50.82M+227.8%
- 2002$15.51M+0.3%
- 2001$15.46M-64.6%
- 2000$43.71M+41.5%
- 1999$30.90M-6.9%
- 1998$33.20M+8.9%
- 1997$30.50M+32.6%
- 1996$23.00M-16.1%
- 1995$27.40M+18.1%
- 1994$23.20M+118.9%
- 1993$10.60M-7.8%
- 1992$11.50M-309.1%
- 1991−$5.50M+323.1%
- 1990−$1.30M—
Gross Profit values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current gross profit (TTM) is $12.61B. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Regeneron Pharmaceuticals (REGN) gross profit totalled $12.24B – edged up 0.1% year-over-year.
Regeneron Pharmaceuticals gross profit compound annual growth for the 2020–2025 (5 years) window is +11.4%, sustaining 3 straight years of year-over-year growth.
Regeneron Pharmaceuticals gross profit peaked at $13.35B in 2021; the latest annual figure is $12.24B in 2025 (8.3% below peak).
2021 marks the peak gross profit at $13.35B, with the historical low of −$5.50M recorded in 1991.
Regeneron Pharmaceuticals Gross Profit by Year
Regeneron Pharmaceuticals Gross Profit 2025: $12.24B
2025's gross profit for Regeneron Pharmaceuticals came in at $12.24B, edged up 0.1% from 2024.
Regeneron Pharmaceuticals Gross Profit 2024: $12.23B
Regeneron Pharmaceuticals posted gross profit of $12.23B in 2024, grew 12.5% from 2023.
Regeneron Pharmaceuticals Gross Profit 2023: $10.87B
In 2023, Regeneron Pharmaceuticals reported gross profit of $10.87B, edged up 3.9% from 2022.
Regeneron Pharmaceuticals Gross Profit 2022: $10.47B
Regeneron Pharmaceuticals gross profit in 2022 was $10.47B, declined 21.6% below 2021.
Regeneron Pharmaceuticals Gross Profit 2021: $13.35B
Regeneron Pharmaceuticals gross profit in 2021 was $13.35B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Gross Profit
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation